Combretastatin-induced hypertension and the consequences for its combination with other therapies.

Abstract

PURPOSE Combretastatin A-4 phosphate (CA4P) is a promising vascular disrupting agent in cancer treatment, but elicits hypertension in patients. The aim of this study was to use a mouse model to investigate whether hypertension or its modification influenced the treatment efficacy of CA4P in combination with other therapies. MATERIAL AND METHODS C3H… (More)
DOI: 10.1016/j.vph.2010.10.002

Topics

Cite this paper

@article{Busk2011CombretastatininducedHA, title={Combretastatin-induced hypertension and the consequences for its combination with other therapies.}, author={Morten Busk and Anja Bille Bohn and Marianne Skals and T. W. M. Wang and Michael Robert Horsman}, journal={Vascular pharmacology}, year={2011}, volume={54 1-2}, pages={13-7} }